Harold Moses, MD
Neurology · Nashville, TNNPI 1417031535
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $277,564 of the $438,198 with a category attached, or 63.3%. 13 manufacturers reported payments, led by Biogen at 25.2% of the total. Reporting peaked in 2019 at $138,885 and has fallen 84.5% since, to $21,593 in 2025. Among neurology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 378 payments — averaging $1159.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$110K
- EMD Serono, Inc.$78K
- AstraZeneca$50K
- Genentech USA, Inc.$45K
- Novartis$32K
- TG Therapeutics, Inc.$31K
- plus $92K from 7 others
Across 33 payments — averaging $10,299 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$213K
- Novartis$116K
- Mallinckrodt Enterprises LLC$10K
- EMD Serono, Inc.$695
What the payments were for
- Consulting fees$119,37227%
- Speaking & faculty fees$277,56463%
- Travel & lodging$30,5557%
- Food & beverage$10,5622%
- Education$1460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 71 | $110,341 |
| EMD Serono, Inc. | 61 | $78,107 |
| AstraZeneca | 57 | $50,104 |
| Genentech USA, Inc. | 39 | $45,042 |
| Novartis | 31 | $32,427 |
| TG Therapeutics, Inc. | 25 | $30,621 |
| Bristol Myers Squibb | 29 | $28,584 |
| Amgen | 31 | $28,245 |
| E.r. Squibb & Sons, L.L.C. | 17 | $26,016 |
| Sanofi | 11 | $4,855 |
| Genentech, Inc. | 4 | $1,640 |
| Ares Trading SA | 1 | $1,590 |
| Johnson & Johnson | 1 | $625 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$438,198 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MavencladCladribine | 18 | $1,243,129 |
| Kesimpta PenOfatumumab | 107 | $883,779 |
| TecfideraDimethyl Fumarate | 57 | $581,967 |
| CopaxoneGlatiramer Acetate | 93 | $519,983 |
| SolirisEculizumab | 11 | $487,353 |
| GilenyaFingolimod Hcl | 39 | $368,023 |
| RebifInterferon Beta-1a/Albumin | 14 | $223,875 |
| VumerityDiroximel Fumarate | 26 | $206,999 |
| Teriflunomide | 44 | $205,609 |
| BetaseronInterferon Beta-1b | 23 | $204,891 |
| Avonex (4 Pack)Interferon Beta-1a | 24 | $185,177 |
| AubagioTeriflunomide | 20 | $181,686 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 17 | $177,129 |
| FingolimodFingolimod Hcl | 52 | $146,899 |
| Dalfampridine ErDalfampridine | 123 | $101,489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Mavenclad, Rebif | $78,107 | $1,467,00432 claims |
| BiogenTecfidera, Vumerity, Avonex (4 Pack) | $110,341 | $974,143107 claims |
| AstraZenecaSoliris | $50,104 | $487,35311 claims |
| NovartisGilenya | $32,427 | $368,02339 claims |
| SanofiAubagio | $4,855 | $181,68620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 361 neurology providers in Tennessee.
Other neurology in Nashville
- Daniel ClaassenNashville$285K
- Francesca BagnatoNashville$167K
- Philip CharlesNashville$132K
- Benjamin HoffmanNashville$124K
- Joy DerwenskusNashville$107K
- James EatonNashville$85K
- Elizabeth FerlugaNashville$77K
- Britt StoneNashville$75K
- Lavanya NagineniNashville$43K
- Amy BrownNashville$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.